SEEL - Seelos Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3000
+0.2800 (+27.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.0200
Open1.0300
Bid1.2900 x 1000
Ask1.3000 x 4000
Day's Range1.0300 - 1.3899
52 Week Range0.4200 - 2.8700
Volume4,096,872
Avg. Volume1,200,460
Market Cap58.435M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Seelos Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims.

    NEW YORK, May 19, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Seelos Therapeutics,.

  • GlobeNewswire

    Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to discuss the unmet medical needs in suicide and depression on Tuesday, May 26, 2020 at 1:00 p.m. Eastern Time. The call will feature a discussion with Distinguished University Health Professor Emeritus at the University of South Florida College of Medicine, David V. Sheehan, MD, MBA. Dr. Sheehan will discuss the unmet medical needs in treating suicidal patients with depression and other mental health conditions.

  • GlobeNewswire

    Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

    NEW YORK, May 18, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.

  • GlobeNewswire

    Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Judith Dunn, Ph.D. to its Board of Directors. Dr. Dunn has had an extensive career in the pharmaceutical and biotechnology industries having served in various roles at F. Hoffman-La Roche AG from March 2010 through January 2018, including Vice President, Global Head of Clinical Development and Principal Medical Group Leader, Neuroscience.

  • GlobeNewswire

    Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

    NEW YORK, May 15, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.

  • GlobeNewswire

    Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

    NEW YORK, May 12, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.

  • GlobeNewswire

    Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

    NEW YORK, May 04, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.

  • GlobeNewswire

    Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

    NEW YORK, April 30, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.

  • GlobeNewswire

    Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provides its first quarter business update and pipeline developments. While the COVID-19 outbreak is reaching unprecedented pandemic levels globally, Seelos empathizes with those experiencing the devastating loss of life and the transformation of their daily lives. Seelos is on the frontline of mental health research and is progressing on schedule with its clinical development of SLS-002 in Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

  • GlobeNewswire

    Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced additional interim data from its Phase I studies of Intranasal Racemic Ketamine (SLS-002). Seelos also announced that it completed its Type C meeting with the U.S. Food and Drug Administration (FDA) as scheduled to discuss the protocol design for a study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

  • GlobeNewswire

    Seelos Therapeutics Announces Closing of Public Offering of Common Stock

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. The net proceeds to Seelos from this offering are expected to be approximately $3.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.

  • GlobeNewswire

    Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

  • GlobeNewswire

    Seelos Therapeutics Announces Proposed Public Offering of Common Stock

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has commenced a proposed underwritten public offering of shares of common stock. In addition, the Company intends to grant the underwriters an option to purchase up to an additional 15% of the aggregate number of shares of common stock sold in the offering on the same terms and conditions to cover over-allotments, if any. All of the shares of common stock in the offering will be sold by Seelos.

  • GlobeNewswire

    Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has received a written response from the European Medicines Agency (EMA), in lieu of a face to face meeting, offering guidance for Seelos’ planned European study of SLS-005 (IV trehalose) in patients with mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome. Based upon the written response from the EMA, Seelos will design an open-label, non-placebo controlled, Phase IIb/III pivotal study for the treatment of patients with Sanfilippo syndrome types A and B in the European Union (EU).

  • GlobeNewswire

    Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007

    NEW YORK, March 06, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.

  • GlobeNewswire

    Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March

    Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 --.

  • Raj Mehra Is The Founder of Seelos Therapeutics, Inc. (NASDAQ:SEEL) And They Just Spent US$100k On Shares
    Simply Wall St.

    Raj Mehra Is The Founder of Seelos Therapeutics, Inc. (NASDAQ:SEEL) And They Just Spent US$100k On Shares

    Even if it's not a huge purchase, we think it was good to see that Raj Mehra, the Founder of Seelos Therapeutics, Inc...

  • GlobeNewswire

    Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 999,999 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

  • Did You Manage To Avoid Seelos Therapeutics's (NASDAQ:SEEL) Devastating 73% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Seelos Therapeutics's (NASDAQ:SEEL) Devastating 73% Share Price Drop?

    Seelos Therapeutics, Inc. (NASDAQ:SEEL) shareholders should be happy to see the share price up 26% in the last...

  • GlobeNewswire

    Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced an update to its Parkinson’s Disease program SLS-007. Seelos is to begin an in-vivo study delivering SLS-007 by an Adeno-Associated Virus (AAV) vector making the program Seelos’ second gene therapy approach for Parkinson’s Disease (PD). Seelos is currently producing the viral vectors and preparing animals for this study.

  • GlobeNewswire

    Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced an update regarding its development programs for SLS-005 (trehalose) in Europe and the U.S. Seelos has scheduled a meeting in March 2020 to meet with the European Medicines Agency (EMA) to seek scientific advice and protocol assistance for a European clinical study of SLS-005 in patients with Sanfillipo syndrome type A and B. The EMA provides support, including regulatory guidance and incentives, for the research and development of medicines for rare diseases in the European Union (EU).

  • GlobeNewswire

    Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced interim data from its Phase I study of Intranasal Racemic Ketamine (SLS-002). Interim data from study SLS-002-101 demonstrated that 60mg of SLS-002, when administered as a monotherapy and in combination with an oral antidepressant, was generally safe and well-tolerated. The interim results from the study have not revealed any new or unique safety signals, there were no serious adverse events (SAEs), and only one of 42 subjects discontinued the trial prematurely (withdrawal on the last day of dosing due to an AE but completed the evaluation).

  • GlobeNewswire

    Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the scheduling of a Type C meeting with the U.S. Food and Drug Administration (FDA) in March 2020. Seelos will seek guidance for an adaptive Phase III trial of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

  • GlobeNewswire

    Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors

    Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr. Smith is a business leader, entrepreneur, medical doctor, author and philanthropist who has held various C-Suite and board positions in the biopharmaceutical industry.

  • GlobeNewswire

    Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33rd Annual National MPS Society Family Conference, December 19-21 in Orlando, FL. Seelos plans to study SLS-005 (trehalose) in Mucopolysaccharidosis Type III (MPS III), also known as Sanfilippo Syndrome.